The prognostic importance of features of myometrial invasion in endometrial endometrioid carcinoma
Archives of Gynecology and Obstetrics · 2025
DOI: 10.1007/s00404-025-08103-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, 2025. Verfasst von Maya Pasternak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Myometrium, Carcinoma, Endometrioid. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ben-Gurion University.
Abstract (Originalsprache)
Purpose
The depth of myometrial invasion (MI) is known to have a prognostic value in endometrial carcinoma (EC), and the FIGO 50% cutoff is widely accepted; however, recent studies have suggested other measurements such as the absolute depth of invasion and tumor-free distance (TFD) from the serosal surface to also be predictive. The aim of this study was to assess the association between the FIGO cutoff and other measures with overall survival and disease-free survival of patients.
Methods
This is a retrospective analysis of a cohort of 248 women diagnosed with stage I endometrioid endometrial carcinoma, treated at Soroka University Medical Center between 2006 and 2020. Clinical and pathological data were collected and analyzed. ROC analysis was used to define the best cutoffs in all three categories (MI, absolute depth and TDF). Survival analyses were then conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards regression.
Results
Absolute myometrial invasion (MI) to the depth of 1 cm significantly predicted overall survival (log-rank, p = 0.009) in univariate analysis; however, this significance was not maintained in multivariate analysis. Additionally, a 33% MI cutoff demonstrated potential for better outcome prediction as compared to the commonly used 50% MI threshold, though it did not reach statistical significance. Tumor-free distance (TFD) from the serosal surface was not significantly associated with outcome.
Conclusions
MI depth of more than 1 cm may serve as a meaningful prognostic indicator. Additionally, a cutoff of 33% MI probably has a better prognostic value than the current 50% cutoff. These findings show a promising direction for future research, emphasizing the need for larger cohorts and multicenter studies to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
- Department of Obstetrics and Gynecology, Soroka University Medical Center, Beersheba, Israel.
- The Institute of Pathology, Soroka University Medical Center, Beersheba, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel. ruthsha@bmc.gov.il.
- The Institute of Pathology, Barzilai University Medical Center, Ha'Histadrut Street 2, Ashkelon, Israel. ruthsha@bmc.gov.il.
ORCID-Profile: Benzion Samueli
Förderung
- Ben-Gurion University
Zitieren
APA
Pasternak, M., Kessous, R., Samueli, B., Dreiher, J., Meirovitz, M., Davidesko, S., & Shaco Levy, R. (2025). The prognostic importance of features of myometrial invasion in endometrial endometrioid carcinoma. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-025-08103-6
Vancouver
Pasternak M, Kessous R, Samueli B, Dreiher J, Meirovitz M, Davidesko S, et al. The prognostic importance of features of myometrial invasion in endometrial endometrioid carcinoma. Archives of Gynecology and Obstetrics. 2025. doi:10.1007/s00404-025-08103-6
BibTeX
@article{Pasternak2025,
author = {Pasternak, Maya and Kessous, Roy and Samueli, Benzion and Dreiher, Jacob and Meirovitz, Mihai and Davidesko, Sharon and Shaco Levy, Ruthy},
title = {The prognostic importance of features of myometrial invasion in endometrial endometrioid carcinoma},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
doi = {10.1007/s00404-025-08103-6}
}
EUVIMED